P48 | LONG-TERM PROGRESSION-FREE SURVIVAL BENEFIT WITH CILTACABTAGENE AUTOLEUCEL IN STANDARD-RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA

Introduction. CARTITUDE-4 (NCT04181827) enrolled patients with lenalidomide-refractory multiple myeloma (MM) after 1–3 prior lines of therapy (pLOT) and showed a significant benefit of ciltacabtagene autoleucel (cilta-cel) over established triplet regimens. However, the benefit of cilta-cel for pat...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	D. Dytfeld, L.J. Costa, A. Oriol, S. Manier, P.M. Voorhees, Y. Lin, M. Htut, W. Roeloffzen, P. J. Ho, U. Shah, M. Zhao, Q. Li, A. Balogh, K. Li, A. Slaughter, N. Benachour, C. Lonardi, A. Ghosh, H. Sun, N. Lendvai, T. Lengil, N. Patel, M. Koneru, E. Florendo, O. Costa Filho, V. Mahajan, P. Rodríguez-Otero, C. Strouse, A.K. Stewart, S. Sidana
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Ferrata Storti Foundation 2026-04-01
Ráidu:	Haematologica
Liŋkkat:	https://haematologica.org/article/view/14061
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!